aiqbench takeAI Products
aiqbench analysis
This acquisition signals OpenAI's strategic pivot toward applying large-scale AI models directly to biological data and drug discovery workflows. By integrating Orchestra Bio with its Rosalind platform, the company aims to accelerate the translation of AI capabilities into tangible pharmaceutical outcomes.
1
Source covering36Kr
OpenAI收购生物医药研发平台Orchestra Bio
36Kr1 min read
OpenAI已完成对生物医药研发协作平台Orchestra Bio的收购，将把其与自身现有的生命科学AI研发平台Rosalind进行深度整合。（财联社）
Read the full article at 36KrRelated coverage
AI Products
OpenAI acquires Orchestra Bio to bring AI agents into drug development
SiliconANGLE · Oct 20, 2026
Chips & Infra
[AINews] DeepSeek DeepInfer: Open Source SOTA Inference running 155T toks/day/cluster making $22m/day at ~80% margin for a 81 day payback
Latent Space · Oct 21, 2026
AI Products
OpenAI acquires Orchestra Bio
OpenAI · Oct 20, 2026
AI Products
OpenAI acquires startup Orchestra Bio to beef up its biotech business
TechCrunch · Oct 20, 2026